Tag: IMM1104
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Uni… –...
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutationPhase 1/2a clinical trial with IMM-1-104 underway in patients...